Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its competitors? We will compare Adaptive Biotechnologies to related companies based on the strength of its dividends, profitability, analyst recommendations, risk, earnings, institutional ownership and valuation.
Insider & Institutional Ownership
99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 54.0% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Adaptive Biotechnologies and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Adaptive Biotechnologies | $276.98 million | -$59.50 million | -65.58 |
| Adaptive Biotechnologies Competitors | $2.33 billion | $55.11 billion | -7.39 |
Adaptive Biotechnologies’ competitors have higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Adaptive Biotechnologies and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adaptive Biotechnologies | -23.67% | -23.95% | -8.01% |
| Adaptive Biotechnologies Competitors | -538.84% | 77.19% | -13.52% |
Analyst Recommendations
This is a breakdown of recent ratings for Adaptive Biotechnologies and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adaptive Biotechnologies | 1 | 1 | 6 | 0 | 2.62 |
| Adaptive Biotechnologies Competitors | 957 | 3187 | 5522 | 178 | 2.50 |
Adaptive Biotechnologies presently has a consensus price target of $30.31, indicating a potential upside of 2.72%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 0.56%. Given Adaptive Biotechnologies’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Adaptive Biotechnologies is more favorable than its competitors.
Risk & Volatility
Adaptive Biotechnologies has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies’ competitors have a beta of 0.94, indicating that their average share price is 6% less volatile than the S&P 500.
Summary
Adaptive Biotechnologies beats its competitors on 7 of the 13 factors compared.
About Adaptive Biotechnologies
Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
